In Silico Designed MRNA Vaccines Targeting CA-125 Neoantigen in Breast and Ovarian Cancer

Overview

Journal Vaccine

Specialty Allergy & Immunology

Date 2023 Feb 22

PMID 36813666

Authors

Lingeng Lu

Wenxue Ma

Caroline H Johnson

Sajid A Khan

Melinda L Irwin

Lajos Pusztai

Affiliations

Soon will be listed here.

Abstract

Somatic mutation-derived neoantigens are associated with patient survival in breast and ovarian cancer. These neoantigens are targets for cancer, as shown by the implementation of neoepitope peptides as cancer vaccines. The success of cost-effective multi-epitope mRNA vaccines against SARS-Cov-2 in the pandemic established a model for reverse vaccinology. In this study, we aimed to develop an in silico pipeline designing an mRNA vaccine of the CA-125 neoantigen against breast and ovarian cancer, respectively. Using immuno-bioinformatics tools, we predicted cytotoxic CD8 T cell epitopes based on somatic mutation-driven neoantigens of CA-125 in breast or ovarian cancer, constructed a self-adjuvant mRNA vaccine with CD40L and MHC-I -targeting domain to enhance cross-presentation of neoepitopes by dendritic cells. With an in silico ImmSim algorithm, we estimated the immune responses post-immunization, showing IFN-γ and CD8 T cell response. The strategy described in this study may be scaled up and implemented to design precision multi-epitope mRNA vaccines by targeting multiple neoantigens.

Citing Articles

Design of a Multiepitope Pan-Proteomic mRNA Vaccine Construct Against African Swine Fever Virus: A Reverse Vaccinology Approach.

Sira E, Fajardo L, Banico E, Odchimar N, Orosco F Vet Med Int. 2025; 2025():2638167.

PMID: 39803351 PMC: 11724734. DOI: 10.1155/vmi/2638167.

Advances in mRNA LNP-Based Cancer Vaccines: Mechanisms, Formulation Aspects, Challenges, and Future Directions.

Ramadan E, Ahmed A, Naguib Y J Pers Med. 2024; 14(11).

PMID: 39590584 PMC: 11595619. DOI: 10.3390/jpm14111092.

Emerging strategies to overcome ovarian cancer: advances in immunotherapy.

Massariol Pimenta T, Carlos de Souza J, da Silva Martins B, Silva Butzene S, Simoes Padilha J, Ganho Marcal M Front Pharmacol. 2024; 15:1490896.

PMID: 39564107 PMC: 11573523. DOI: 10.3389/fphar.2024.1490896.

Multimodal ultrasound plus tumor markers demonstrates a high value in enhanced diagnosis of breast cancer.

Li N, Li M, Zhou F Am J Transl Res. 2024; 16(10):5497-5506.

PMID: 39544801 PMC: 11558377. DOI: 10.62347/QVCI6027.

mRNA-based therapeutic strategies for cancer treatment.

Taibi T, Cheon S, Perna F, Vu L Mol Ther. 2024; 32(9):2819-2834.

PMID: 38702886 PMC: 11403232. DOI: 10.1016/j.ymthe.2024.04.035.

References

Mi Z, Feng Z, Li C, Yang X, Ma M, Rong P . -Mediated Cancer Therapy: An Innovative Therapeutic Strategy. J Cancer. 2019; 10(20):4765-4776. PMC: 6775532. DOI: 10.7150/jca.32650. View

Ott P, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N . A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell. 2020; 183(2):347-362.e24. DOI: 10.1016/j.cell.2020.08.053. View

Hyun J, Jun S, Lim H, Cho H, You S, Ha S . Engineered Attenuated Expressing Neoantigen Has Anticancer Effects. ACS Synth Biol. 2021; 10(10):2478-2487. DOI: 10.1021/acssynbio.1c00097. View

Das K, Belnoue E, Rossi M, Hofer T, Danklmaier S, Nolden T . A modular self-adjuvanting cancer vaccine combined with an oncolytic vaccine induces potent antitumor immunity. Nat Commun. 2021; 12(1):5195. PMC: 8408233. DOI: 10.1038/s41467-021-25506-6. View

Balachandran V, Luksza M, Zhao J, Makarov V, Moral J, Remark R . Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature. 2017; 551(7681):512-516. PMC: 6145146. DOI: 10.1038/nature24462. View

Sahin U, Derhovanessian E, Miller M, Kloke B, Simon P, Lower M . Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017; 547(7662):222-226. DOI: 10.1038/nature23003. View

Wang J, Song W, Li Y, Chen W, Yang D, Zhong G . Improved expression of secretory and trimeric proteins in mammalian cells via the introduction of a new trimer motif and a mutant of the tPA signal sequence. Appl Microbiol Biotechnol. 2011; 91(3):731-40. DOI: 10.1007/s00253-011-3297-0. View

Narang P, Chen M, Sharma A, Anderson K, Wilson M . The neoepitope landscape of breast cancer: implications for immunotherapy. BMC Cancer. 2019; 19(1):200. PMC: 6399957. DOI: 10.1186/s12885-019-5402-1. View

Roszik J, Haydu L, Hess K, Oba J, Joon A, Siroy A . Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Med. 2016; 14(1):168. PMC: 5078889. DOI: 10.1186/s12916-016-0705-4. View

10.

Colaprico A, C Silva T, Olsen C, Garofano L, Cava C, Garolini D . TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2015; 44(8):e71. PMC: 4856967. DOI: 10.1093/nar/gkv1507. View

11.

Dimitrov I, Bangov I, Flower D, Doytchinova I . AllerTOP v.2--a server for in silico prediction of allergens. J Mol Model. 2014; 20(6):2278. DOI: 10.1007/s00894-014-2278-5. View

12.

Gavrielatou N, Vathiotis I, Economopoulou P, Psyrri A . The Role of B Cells in Head and Neck Cancer. Cancers (Basel). 2021; 13(21). PMC: 8582491. DOI: 10.3390/cancers13215383. View

13.

Milne K, Kobel M, Kalloger S, Barnes R, Gao D, Gilks C . Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One. 2009; 4(7):e6412. PMC: 2712762. DOI: 10.1371/journal.pone.0006412. View

14.

Rapin N, Lund O, Bernaschi M, Castiglione F . Computational immunology meets bioinformatics: the use of prediction tools for molecular binding in the simulation of the immune system. PLoS One. 2010; 5(4):e9862. PMC: 2855701. DOI: 10.1371/journal.pone.0009862. View

15.

Magnan C, Zeller M, Kayala M, Vigil A, Randall A, Felgner P . High-throughput prediction of protein antigenicity using protein microarray data. Bioinformatics. 2010; 26(23):2936-43. PMC: 2982151. DOI: 10.1093/bioinformatics/btq551. View

16.

Dhanda S, Gupta S, Vir P, Raghava G . Prediction of IL4 inducing peptides. Clin Dev Immunol. 2014; 2013:263952. PMC: 3893860. DOI: 10.1155/2013/263952. View

17.

Strickland K, Howitt B, Shukla S, Rodig S, Ritterhouse L, Liu J . Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016; 7(12):13587-98. PMC: 4924663. DOI: 10.18632/oncotarget.7277. View

18.

Gupta S, Kapoor P, Chaudhary K, Gautam A, Kumar R, Raghava G . Peptide toxicity prediction. Methods Mol Biol. 2015; 1268:143-57. DOI: 10.1007/978-1-4939-2285-7_7. View

19.

Gunderson A, Coussens L . B cells and their mediators as targets for therapy in solid tumors. Exp Cell Res. 2013; 319(11):1644-9. PMC: 3743954. DOI: 10.1016/j.yexcr.2013.03.005. View

20.

Li X, Pasche B, Zhang W, Chen K . Association of MUC16 Mutation With Tumor Mutation Load and Outcomes in Patients With Gastric Cancer. JAMA Oncol. 2018; 4(12):1691-1698. PMC: 6440715. DOI: 10.1001/jamaoncol.2018.2805. View